NCT06532357View on ClinicalTrials.gov

A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.

CompletedOBSERVATIONAL
Enrollment

1,536

Participants

Timeline

Start Date

June 9, 2024

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions
Migraine
Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06532357 - A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users. | Biotech Hunter | Biotech Hunter